Precision BioSciences (DTIL) announced that the FDA has granted Orphan Drug Designation for PBGENE-DMD for the treatment of Duchenne muscular dystrophy.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DTIL:
- Precision BioSciences Duchenne muscular dystrophy treatment gets orphan status
- Precision BioSciences announces additional PBGENE-DMD preclinical data
- Precision BioSciences: Strong Buy Rating Based on Promising Gene Editing Innovations and Market Positioning
- Precision granted Rare Pediatric Disease Designation for PBGENE-DMD
- Precision BioSciences: Promising Gene Editing Platform Targets Chronic HBV and DMD with Strategic Focus